Is CRISPR Therapeutics a Buy? [The Motley Fool]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: The Motley Fool
Is CRISPR Therapeutics a Buy? In the volatile world of biotech, investors can find a number of promising markets that could see significant growth in the years to come. Gene editing is one of these markets that has tremendous potential for growth, with some research reports showing the sector could reach $9. billion by 0. Considering that in 08, the gene-editing market was worth only $.7 billion; this works out to an impressive .7% annual growth rate. While few biotech stocks CRISPR Therapeutics ( NASDAQ:CRSP Amid this wave of excitement, shares of CRISPR have risen by .8% so far in 09. While CRISPR will have to clear a few hurdles before its gene-editing drugs can hit the markets, there's a strong case to be made for this stock becoming a leader in the space. Let's take a look at some of the main therapies CRISPR is developing at the moment and how exactly it compares to its competition. IMAGE SOURCE: GETTY IMAGES. Potential breakthrough No. : Sickle cell and thalassemia treatments C
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- Is CRISPR Therapeutics AG (CRSP) the Most Promising Biotech Stock According to Hedge Funds? [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why [Yahoo! Finance]Yahoo! Finance
- This Healthcare Growth Stock Could Be a Steal of a Deal Right Now [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics AG (NASDAQ: CRSP) had its price target lowered by analysts at Royal Bank of Canada from $60.00 to $53.00. They now have a "sector perform" rating on the stock.MarketBeat
CRSP
Earnings
- 8/5/24 - Miss
CRSP
Sec Filings
- 10/15/24 - Form 4
- 10/15/24 - Form 4
- 8/12/24 - Form 4
- CRSP's page on the SEC website